SRPT — Sarepta Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $11.53bn
- $11.09bn
- $1.24bn
- 49
- 11
- 80
- 44
Annual cashflow statement for Sarepta Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -715 | -554 | -419 | -703 | -536 |
| Depreciation | |||||
| Non-Cash Items | 295 | 80.6 | 35.8 | 376 | 472 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -66.9 | 554 | -98.2 | -39.5 | -481 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -456 | 107 | -443 | -325 | -501 |
| Capital Expenditures | -62.7 | -85.7 | -42.6 | -33.3 | -87.3 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 349 | -36 | 538 | -1,014 | -78.5 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 287 | -122 | 495 | -1,047 | -166 |
| Financing Cash Flow Items | -5.03 | -4.84 | -7.76 | -0.716 | -6.89 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 643 | 682 | 562 | 233 | 125 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 473 | 668 | 614 | -1,140 | -542 |